

AMENDED CLAIMS (Rec'd PCT/PTO 28 SEP 2006)

[received by the International Bureau on July 27, 2005(27.07.2005); original claims 1-11 amended; original claim 16 cancelled; remaining claims unchanged (2 pages)]

- [1] (補正後)投与された間葉系幹細胞の損傷組織への遊走・集積を促進するおよび／または投与された間葉系幹細胞の損傷組織からの拡散を抑制するための、薬剤または移植材。
- [2] (補正後)間葉系幹細胞の投与と同時に、連続的にまたは別個に使用するための、請求項1記載の薬剤または移植材。
- [3] (補正後)間葉系幹細胞遊走能促進因子を含む、請求項1又は2記載の薬剤または移植材。
- [4] (補正後)間葉系幹細胞遊走能促進因子が間葉系幹細胞の増殖を促進する、請求項3記載の薬剤または移植材。
- [5] (補正後)再生治療に使用される請求項1～4の何れか1項記載の薬剤または移植材。
- [6] (補正後)変形性関節症、骨折、歯槽骨もしくは顎骨欠損、脳梗塞、心筋梗塞または下肢虚血による損傷組織の再生治療に使用される請求項5記載の薬剤または移植材。
- [7] (補正後)間葉系幹細胞遊走能促進因子がEGF(上皮成長因子)、HB-EGF(ヘパリン結合上皮成長因子)、TGF- α 、トロンビン、PDGF(血小板由来成長因子)、FGF(線維芽細胞成長因子)、ヒアルロン酸、IGF(インスリン様成長因子)、およびHGF(肝細胞増殖因子)から選ばれる、請求項3～6の何れか1項記載の薬剤または移植材。
- [8] (補正後)投与された間葉系幹細胞の損傷組織への遊走・集積を促進する因子および投与された間葉系幹細胞の損傷組織からの拡散を抑制する因子の少なくとも一方の因子を投与することを含む、損傷組織の再生治療方法。
- [9] (補正後)因子が、間葉系幹細胞の投与と同時に、連続的にまたは別個に投与される、請求項8記載の方法。
- [10] (補正後)因子が、間葉系幹細胞遊走能促進因子である、請求項8又は9記載の方法。
- [11] (補正後)損傷組織が、変形性関節症、骨折、歯槽骨もしくは顎骨欠損、脳梗塞、

心筋梗塞または下肢虚血による請求項8～10の何れか1項記載の方法。

- [12] 間葉系幹細胞遊走能促進因子がEGF、HB-EGF、TGF- α 、トロンビン、PDGF、FGF、ヒアルロン酸、IGF、およびHGFから選ばれる請求項10又は11記載の方法。
- [13] 間葉系幹細胞遊走能促進因子が損傷組織に局所投与される請求項10～12の何れか1項記載の方法。
- [14] 間葉系幹細胞遊走能促進因子が注射により投与される請求項13記載の方法。
- [15] 間葉系幹細胞遊走能促進因子が損傷組織に塗布される請求項13記載の方法。
- [16] (削除)

CLAIMS

[1] (Amended) An agent or a transplant for enhancing the migration and accumulation of administered mesenchymal stem cells in an injured tissue and/or suppressing the diffusion of administered mesenchymal stem cells from an injured tissue.

[2] (Amended) The agent or transplant according to claim 1, for administering simultaneously with, or continuously to, or separately from mesenchymal stem cells.

[3] (Amended) The agent or transplant according to claim 1 or 2, which contains a mesenchymal stem cell migration-enhancing factor.

[4] (Amended) The agent or transplant according to claim 3, wherein the mesenchymal stem cell migration-enhancing factor enhances the proliferation of mesenchymal stem cells.

[5] (Amended) The agent or transplant according to any one of claims 1-4, which is used in regeneration therapy.

[6] (Amended) The agent or transplant according to claim 5, which is used in a regeneration therapy of injured tissue resulting from osteoarthritis, bone fracture, loss of alveolar bone or jaw bone, cerebral infarction, myocardial infarction, or lower limb ischemia.

[7] (Amended) The agent or transplant according to any one of claims 3-6, wherein the mesenchymal stem cell migration-enhancing factor is selected from the group consisting of EGF (epidermal growth factor), HB-EGF (heparin-binding epidermal growth factor), TGF- α , thrombin,

AMENDED SHEETS

PDGF (platelet-derived growth factor), FGF (fibroblast growth factor), hyaluronic acid, IGF (insulin-like growth factor), and HGF (hepatocyte growth factor).

[8] (Amended) A method of regeneration therapy for injured tissue, which comprises administering at least either of a factor that enhances the migration and accumulation of administered mesenchymal stem cells in the injured tissue or a factor that suppresses the diffusion of administered mesenchymal stem cells from the injured tissue.

[9] (Amended) The method according to claim 8, wherein the factor is administered simultaneously with, or continuously to, or separately from mesenchymal stem cells.

[10] (Amended) The method according to claim 8 or 9, wherein the factor is a mesenchymal stem cell migration-enhancing factor.

[11] (Amended) The method according to any one of claims 8-10, wherein the injured tissue results from osteoarthritis, bone fracture, loss of alveolar bone or jaw bone, cerebral infarction, myocardial infarction, or lower limb ischemia.

[12] The method according to claim 10 or 11, wherein the mesenchymal stem cell migration-enhancing factor is selected from the group consisting of EGF, HB-EGF, TGF- α , thrombin, PDGF, FGF, hyaluronic acid, IGF, and HGF.

[13] The method according to any one of claims 10-12, wherein the mesenchymal stem cell migration-enhancing factor is administered topically to the injured tissue.

[14] The method according to claim 13, wherein the mesenchymal stem cell migration-enhancing factor is administered by injection.

[15] The method according to claim 13, wherein the mesenchymal stem cell migration-enhancing factor is applied over the injured tissue.

[16] (Deleted)

AMENDED SHEETS
AMENDED SHEETS